Inactive Instrument

Luckwel Pharmaceuticals Inc.

LWEL

US54959L1017

Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2019

July 02, 2019 at 06:03 am

Luckwel Pharmaceuticals Inc. announced earnings results for the full year ended March 31, 2019. For the full year, the company announced net loss was USD 622,526 compared to USD 537,088 a year ago. Basic loss per share from continuing operations was USD 0.005 compared to USD 0.029 a year ago.

Latest news about Luckwel Pharmaceuticals Inc.

Luckwel Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	21-09-07	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	21-06-10	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.075 million in funding from Bounty Company Limited	21-05-13	CI
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.12 million in funding	21-04-19	CI
Luckwel Pharmaceuticals Inc. Announces Address Changes	21-01-04	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019	20-02-13	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2019	19-11-14	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2019	19-07-02	CI
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018	19-02-14	CI
Luckycom Pharmaceuticals Inc. has Changed its Name to Luckwel Pharmaceuticals Inc	18-04-13	CI
Luckwel Pharmaceuticals Inc. has Changed its Ticker to LWEL from LCOM	18-04-13	CI
Luckycom, Inc. will Change its Name to Luckycom Pharmaceuticals Inc	17-04-18	CI
Luckycom Pharmaceuticals Inc. will Change its Ticker to LCOM from LKYM	17-04-18	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	16-05-01	CI
Luckycom Inc Announces Fiscal Year Change from February 28 or 29 to March 31	16-02-11	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	15-05-31	CI
Luckycom Inc Auditor Raises 'Going Concern' Doubt	14-05-14	CI

Chart Luckwel Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Luckwel Pharmaceuticals Inc. creates medicine to cure diseases. The Company is focused on autoimmune disease, human immunodeficiency virus (HIV) / acquired immune deficiency syndrome (AIDS) and infectious diseases. The Companyâs pipelines include LWEL-2120 for the treatment of rheumatoid arthritis (RA), LWEL-2119 for the treatment of HIV and LWEL-2103 for the treatment of COVID-19.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
TRUMP MEDIA & TECHNOLOGY GROUP CORP.	+209.31%	7.06B
CHURCHILL CAPITAL CORP VII	+2.10%	982M
SCREAMING EAGLE ACQUISITION CORP.	-3.96%	954M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+23.71%	800M
ARES ACQUISITION CORPORATION II	+1.77%	664M
E7 GROUP	+7.72%	659M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ADMIRAL ACQUISITION LIMITED	+3.61%	503M

Shell Companies